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The distribution of the T29C TGFβ1 gene polymorphism was analyzed in 198 hypertensives with left ventricular hypertrophy
(LVH) and in 235 hypertensives without LVH. Circulating TGFβ1 levels, procollagen type III levels, microalbuminuria, and left
ventricular geometry and function were evaluated in all the hypertensives with LVH subgrouped according to T29C TGFβ1g e n e
polymorphism. Circulating TGFβ1 was evaluated by ELISA technique, procollagen type III by a speciﬁc radioimmunoassay,
microalbuminuria by radioimmunoassay, and left ventricular geometry and function by echocardiography. All groups were
comparable for gender, age, and sex. Regarding T29C TGFβ1 gene polymorphism, prevalence of TC or CC genotypes was
signiﬁcantly (P<. 05) higher in hypertensives with LVH than hypertensives without LVH TC and CC LVH hypertensives were
characterized by a higher prevalence of subjects with microalbuminuria (P<. 05 TC and CC versus TT), by increased levels
of TGFβ1, procollagen type III, urinary albumin excretion, LVM, LVM/h2.7, and lower values of left ventricular ejection fraction
(P<. 05TCandCCversusTT).OurdatasuggestthatT29CTGFβ1genepolymorphismwasassociatedwithclinicalcharacteristics
adequate to recognize a subset of LVH hypertensives with a higher severity of hypertension.
1.Introduction
Hypertension represents the most common powerful risk
factor for cardiovascular morbidity and mortality [1]. High
blood pressure is associated with adverse morphological and
functional changes in the cardiovascular and renal system,
including left ventricular hypertrophy (LVH), microalbu-
minuria and progressive renal and heart disease.
The disproportional accumulation of ﬁbrous tissue is the
major characteristic of the adverse structural remodelling
of cardiac tissue in hypertensives promoting systolic and
diastolic dysfunction [2–5].
Transforming growth factor β1( T G F β1) is a multifunc-
tional cytokine and its gene has been found in position
19q13.2, 19q13.1 on chromosome 19 and it has 7 exons and
the length of the whole gene is 17.52kb.
TGFβ1 overproduction acts on cardiomyocytes as well
as on cardiac ﬁbroblasts inducing cardiac ﬁbrosis and
hypertrophy [6, 7]. In addition, the reduction in circulating
TGFβ1 through a block of the renin-angiotensin system
(RAS) was reported to be associated with an improvement
of renal function and a reversion in LVH [8, 9]. Moreover,
recent experimental data indicate that blockade of the TGFβ,
throughanovelorallyspeciﬁcinhibitoroftheTGFβ receptor
1, results in signiﬁcant improvement of deleterious cardiac
remodelling after infarction [10].
Production of TGFβ1i si np a r tu n d e rg e n e t i cc o n t r o l
[11]. Eight single nucleotide polymorphism (SNPs)h a v e2 International Journal of Hypertension
Table 1: Clinical characteristics and distribution of Leu10 →Pro10 genotypes in hypertensives (Ht) with and without left ventricular
hypertrophy (LVH).
Ht with LVH Ht without LVH P=
n. 198 235
Age 50 ± 10 49 ± 10 .300
Gender (F/M) 90/108 124/111 .590
BMI (Kg/m2)2 5 ± 62 4 ± 6 .085
WHR 0.86 ± 0.1 0.85 ± 0.1 .300
SBP (mm/Hg) 144 ± 15 143 ± 16 .505
DBP (mm/Hg) 88 ± 98 7 ± 10 .279
MBP (mm/Hg) 106 ± 9 105 ± 9 .250
Ht treated (%) 94.4% (187/198) 94.9% (223/235) .987∗
Diuretics 9% (17/187) 12.1% (27/223) .394∗
ACEi 58.8% (110/187) 61.8% (138/223) .605∗
ARB 42.8% (80/187) 40.3% (90/223) .607∗
CaCB 11.8% (22/187) 17.3% (30/223) .199∗
Duration of treatment (yrs) 6.5 ± 3.3 6.2 ± 3.9 .393
T29C (Leu10 →Pro)
TT 15.1% (30/198) 30.6% (72/235) .0418
TC 64.7%∗ (128/198) 49.8% (117/235) .0434
CC 20.2%∗ (40/198) 19.6% (46/235) .0472
TC + CC 84.9% 69.4% .0466
∗z test.
F: Female; M: Male; BMI: Body mass index; WHR: Waist hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure;
MBP: mean blood pressure. ACEi: angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CaCB: calcium channel blockers. n.s. = not
signiﬁcant.
been described in TGFβ1 gene and related to its production
and to hypertension and cardiovascular disease [11, 12]. Two
SNPs are located at positions 29 and 74 of the translated
sequence of TGFβ1 and give rise to amino acid substitutions
at positions 10 (Leu10 → Pro) and 25 (Arg25 → Pro)
in the signal peptide of TGFβ1, respectively [12, 13]. The
T29C was reported to inﬂuence steady-state concentrations
of TGFβ1 mRNA in peripheral blood mononuclear cells
and serum levels of TGFβ1, and the G74C was found to be
related to TGFβ1 production in peripheral blood leukocytes
[13, 14]. In addition, the Arg25 allele was associated with
risk of hypertension in the normotensives [12, 15]a n d
with myocardial infarction [12, 16] compared to the Pro25
allele. On the contrary, no studies have been addressed
the evaluation of the role of T29 → Cp o l y m o r p h i s mo f
TGFβ1 gene on left ventricular geometry and function in
hypertensive patients [14, 16].
The aim of this study was to investigate the relationship
between T29C TGFβ1 gene polymorphism (rs1800470),
LVH and clinical severity of hypertension.
In particular, circulating TGFβ1, procollagen type III
levels, microalbuminuria, left ventricular geometry and
function were evaluated in hypertensive patients and related
to genotype proﬁle.
2.MaterialsandMethods
2.1. Patients. Subjects eligible for the study were screened at
the antihypertensive center of the Department of Internal
Medicine, University of Palermo (Italy). The study pop-
ulation consisted of hypertensive subjects with age ≤65
years. Each patient gave a written consent after received
a detailed description of study procedure. The study was
approved by Ethics Committee of our Institution. Subjects
under antihypertensive treatment or with a casual blood
pressure (SBP) ≥140mmHg and/or with casual diastolic
blood pressure (DBP) ≥90mmHg obtained with a standard
sphygmomanometer after 5 minute of rest at three indepen-
dent occasions with patients sitting were considered hyper-
tensives. Exclusion criteria included secondary hypertension,
endocrinal disease and diabetes mellitus, cardiovascular
diseases (deﬁned as myocardial infarction and recent stroke
withinprevious6months,heartfailure),severechronicrenal
failure, alcoholism and psychiatric problems.
433 hypertensive subjects fulﬁlled the inclusion criteria
and they were grouped according to the presence or absence
of LVH, following standard echocardiographic criteria. In
particular all the hypertensives with LVM/h2.7 ≥50g/m2.7for
men and ≥47g/m2.7for women were considered to have LVH
[19].Accordingly,198hypertensiveswithLVHand235with-
out LVH were recognized and studied. In addition 94.4%
(187/198pts) of LVH hypertensives and 94.9% (223/235pts)
of no-LVH hypertensives were under antihypertensive treat-
ment at the beginning of the study. The percent of anti-
hypertensive drugs utilized, such as duration of treatment,
was not signiﬁcantly diﬀerent in all hypertensive groups
(Table 1), also when subgrouped according to T/C genotypes
(Table 2).International Journal of Hypertension 3
Table 2: Distribution of clinical measurements in the hypertensives with left ventricular hypertrophy subgrouped according to Leu10 →
Pro10 TGFβ1g e n o t y p e s ∗.
TT n. 30 TC n. 128 CC n. 40
Gender(F/M) 16/14 60/68 14/26
Age 55 ± 10 50 ± 95 0 ± 9
Weight (Kg) 69 ± 11 72 ± 10 70 ± 9
Height (m) 1.67 ± 0.1 1.65 ± 0.1 1.68 ± 0.1
BMI (Kg/m2)2 4 ± 22 5 ± 22 4 ± 3
WHR 0.85 ± 0.1 0.87 ± 0.1 0.87± 0.1
SBP (mmHg) 143 ± 16 146 ± 16 141 ± 16
DBP (mmHg) 87 ± 10 90 ± 11 89 ± 8
MBP (mmHg) 105 ± 11 108 ± 11 106 ± 9
Antihypertensive drugs
Diuretics 3/30 (10%) 10/128 (7.9%) 4/40 (10%)
ACEi 16/30 (53.4%) 75/128 (58.6%) 19/40 (47.5%)
ARB 12/30 (40%) 58/128 (42.1%) 14/40 (35%)
CaCB 4/30 (13.3%) 12/128 (8.4%) 6/40 (15%)
F: Female; M: Male; BMI: Body mass index; WHR: waist hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MBP: Mean blood pressure;
ACEi: angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CaCB: calcium channel blockers.
∗All variables were not signiﬁcantly diﬀerent among the groups.
2.2. DNA Isolation and Genotyping. Genotyping was per-
formed by investigators blinded to clinical status.
Peripheral venous blood was collected in EDTA from all
the patients and stored at −70◦C.
ThePCRapproachwasusedtoanalyzeSNPinthecoding
regions of TGFβ1.
The study of the TGBβ1 polymorphism was done by
analyzing the sequence. The polymorphism is on exon 1 at
+869 from the beginning of the transcription and generate
an amino acid substitution in position 10 (Leu → Pro). This
studyanalyzedthegenotypesderivedfromthissubstitutions.
PCR was performed on puriﬁed DNA obtained using the
GenElute Blood Genomic Dna Kit by Sigma: which provided
sequence-speciﬁc oligonucleotide primers
T869C:
Forward 5 -TTCCCTCGAGGCCCTCCTA -3 
Reverse 5 -GCCGCAGCTTGGACAGGAT-3 
Brieﬂy, PCR reactions were carried out in a total
volume of 50-μL containing approximately 5μLo fg e n o m i c
DNA(0.1μg/μL), 2μLo ff o r w a r da n dr e v e r s ep r i m e r s
(100ng/μL), 5μLo f1 0× reaction buﬀer (160mM
(NH4)2SO4, 670mM Tris-HCl (pH 8,8 at 25◦C), 15mM
MgCl2,0 ,1 %T w e e n2 0 ) ,4μL of 2mM dNTPs (invitrogen),
4μL of DMSO, 0, 1u of Taq Polymerase.
Ampliﬁcation was carried out in a Robocycler using
cycle parameters of 3 minutes and 30 seconds at 95◦C
(initial denaturation), 35 cycles of 95◦C for 45 seconds
(denaturation), 62◦C for 30 seconds (primer annealing) and
a ﬁnal extension for 10 minutes at 72◦C.
T869C: the PCR generated amplicons with a fragment
size of 294Bp.
All PCR products were resolved on 2% agarose gel with
3μL of ethidium bromide (Figure 1).
1234 M a r k e r
300BP
250BP
294BP
50BP
Figure 1: 2% agar gel for conﬁrming the ampliﬁcation fragment
(294Bp). Subject 1–4, M marker 50Bp (invitrogen).
2.3. Sequencing. P C Rp r o d u c t sw e r es e q u e n c e dt og e n o t y p e
in all the subjects. PCR reactions in 50μL were directly
sequenced by MWG (the full name is Euroﬁns MWG
Operon, see http://www.euroﬁnsdna.com/home.html)a n d
from sequence electropherograms was analysed the pres-
ence of single-nucleotide polymorphisms T869C in all the
subjects (Figure 2). The distribution of SNP TGFβ1g e n e
b e t w e e nb o t hh y p e r t e n s i v eg r o u p sw e r er e p o r t e di nTable 1.
2.4. Biochemical Measurements. Patients underwent a gen-
eral analytical laboratory parameters proﬁle including BUN,
creatinine and clearance, glycaemia, electrolytes (serum
sodium, potassium, chloride), cholesterol by routine labora-
tory methods.
Peripheral venous blood was obtained from each patient
andtheserawereisolatedandstoredat −70◦C.TGFβ1lev els
were determined by using a solid-phase speciﬁc sandwich
ELISA technique (R&D Systems, Inc. Minneapolis, USA)
as previously described [17]. The interassay and intra-
assay variations for determining TGFβ1w e r e8 %a n d6 % ,4 International Journal of Hypertension
TGCGCCCTTCTCCCTGAGGACCTCAGCTTTCCCTCGAGGCCCTCCTACCTTTTGCCGGGAGACCCCCAGCCCCTG
CAGGGGCGGGGCCTCCCCACCACACCAGCCCTGTTCGCGCTCTCGGCAGTGCCGGGGGGCGCCGCCTCCCCCAT
GCCGCCCTCCGGGCTGCGGCTGCTGCC/TGCTGCTGCTACCGCTGCTGTGGCTACTGGTGCTGACGCCTGGCCGG
CCGGCCGCGGGACTATCCACCTGCAAGACTATCGACATGGAGCTGGTGAAGCGGAAGCGCATCGAGGCCATCC
GCGGCCAGATCCTGTCCAAGCTGCGGCTCGCCAGC
Figure 2: Localization scheme of the polymorphism at +869 C/T, situated inside exon 1, positions of the forward and reverse primers of the
294Bp fragment are indicated.
respectively. The sensitivity, hence minum level of detection
of TGFβ1 by sandwich ELISA, was 5pg/mL.
To determine amino-terminal PIIIP, blood samples
w e r et a k e nf r o me a c hp a t i e n ta n ds t o r e da t4 0 ◦C until
manipulation. PIIIP were determined by using a speciﬁc
radioimmunoassay (Orion Diagnostic Finland), as previ-
ously described [18]. The sensitivity of PIIIP was 1ng/mL,
the intra-assay variations ranged from 1.7% to 4.3% and
interassay variations from 3.2% to 5.3%.
2.5. Urinary Albumin Excretion (UAE). To eliminate the
intra-individual day-to-day variability of UAE, three con-
secutive 24-hour urine collections were used. In addition,
to assess the completeness of a 24 hours urine collection,
measurements of urinary rate of clearance of creatinine
were evaluated. UAE was measured by radioimmuno-assay
(limit of detection, 0.1mg/dL; Inter-assay coeﬃcient 3.5%).
Microalbuminuric patients were deﬁned as a level of UAE
≥20 and <300mg/24hours.
2.6. Echocardiographic Measurements. All patients under-
went an echocardiography examination M and B-mode,
by a computerized echocardiography (ESAOTE, Italy) for
the determination of following parameters: left ventricu-
lar telediastolic internal diameter (LVIDd), interventricular
septum (IVSTd), and posterior wall thickness (PWTd).
The Penn convention was used to calculate left ventricular
mass (LVM). LVM was normalized for height to the 2.7
power [19]. The relative wall thickness (RWT) by formula
[(PWTd/LVIDd) × 2] was also calculated. Ejection fraction
from left ventricular end-diastolic and end-systolic volumes
was measured from the apical four chamber view, using
the ellipsoidal single-plane algorithm. Mean ejection frac-
tion was automatically calculated by the echocardiographic
processing system. In our laboratory the ejection fraction
calculated over ﬁve consecutive beats permitted optimal
reproducibility and accuracy [20].
LV relaxation and ﬁlling were evaluated by pulsed-wave
Doppler interrogation of the LV inﬂow tract from the apical
four-chamberview,withthesamplevolumeplacedatthetips
of the mitral valve. After a stable signal of the transmitral
ﬂow velocity was obtained, the Doppler cursor was moved
toward the LV outﬂow tract in the apical ﬁve-chamber view
for recording both mitral and aortic signals, including the
closing click of the aortic valve and the opening click of the
mitral valve. Doppler signals were recorded at high speed
(80–120mm/s) with the subjects in held expiration. An
average of ﬁve beats was used for analysis.
Isovolumic relaxation time (IVRT) was calculated as the
time from the closure click of the aortic valve to the opening
click of the mitral valve. When either the closing or opening
click was not identiﬁed, the time from the end of the aortic
ﬂow to the onset of mitral ﬂow from the continuous wave
interrogation of the LV inﬂow-outﬂow tract was used. Peak
early transmitral ﬂow velocity (E), peak late transmitral ﬂow
velocity (A), and the deceleration time of E velocity (DTE)
were measured at the tips of mitral leaﬂets at the maximum
amplitude of E velocity. DTE was measured as the time from
peakE velocitytothetimewhenE wavedescentinterceptthe
zero line.
2.7.StatisticalAnalysis. Nosamplesizewascalculatedforthe
lack of any information about the main goal of the study.
Continuous variables are reported as mean ± SD. Abso-
lute and relative frequencies are reported when appropriate.
For continuous variables, comparisons among groups were
performed by Kruskall-Wallis test as non parametric analysis
of variance. Multiple pairwise comparisons were made by
the Critchlow-Fligner method. Contingency tables were
analyzed by the Q2 test or the Fisher exact test when possible.
Pairwise comparison between frequencies were made by Z-
test after Chi-square statistical signiﬁcant value. A two tailed
P value <.05 was considered signiﬁcant.
Logistic regression analysis, according to Hosmer and
Lemeshow method [21] has been used to investigate asso-
ciation between TT or TC plus CC genotypes and both
laboratory and clinical measurements. Continuous variables
were put into the model as quintiles.
3. Results
The results of the study are presented in Tables 1–5.
3.1. Distribution of T29C TGFβ1 Genotypes in Hypertensives
With and Without LVH. The distribution of T29C genotypes
in both hypertensive groups has been reported in Table 1.
T h ep r e v a l e n c eo fT C( P = .0434), and TC plus CC (P =
.0466) genotypes, was signiﬁcantly higher in hypertensives
with LVH than hypertensives without LVH (64.7% versus
49.8%, and 84.9% versus 61.4%, respectively).
Genotype frequency distribution in the two groups
of hypertensives occurred according to Hardy-Weinberg
proportions.
Sincegenotypefrequencydistributionwasnotsigniﬁcant
diﬀerent in hypertensives without LVH, only hypertensivesInternational Journal of Hypertension 5
with LVH were further subdivided into three groups, accord-
ing to T/C genotypes.
3.2. Distribution of Clinical Characteristics in Hypertensives
With LVH Subgrouped According to T29C TGFβ1G e n o t y p e s .
The association between genotypes and clinical character-
istics in the three groups of hypertensives with LVH have
been reported in Table 2. All the groups were homogeneous
regarding to age, BMI, WHR and blood pressure. LVH
hypertensives with TC or CC genotype were characterized
by a signiﬁcant higher prevalence of subjects with microal-
buminuria (P<. 0 5T Ca n dC Cv e r s u sT T ) .
No signiﬁcant diﬀerence in the prevalence and duration
of antihypertensive drugs utilized was observed among the
groups (Tables 1 and 2). In addition no signiﬁcant diﬀerence
alsoinstatinadministrationwasobservedamongthegroups.
3.3. Circulating TGFβ1, Type III Collagen, Urinary Albu-
min Excretion and Echocardiographic Parameters. Urinary
albumin excretion, circulating TGFβ1, PIIIP, LVM and
LVM/h2.7levels were signiﬁcantly (P<. 05) higher and left
ventricular ejection fraction values were signiﬁcantly (P<
.05) lower in LVH hypertensives with TC or CC genotype
than those detectable in LVH hypertensives homozygous for
allele T (Tables 3 and 4).
4.Logistic RegressionAnalysis
This analysis indicated an association between higher levels
of PIIIP and TC or CC genotypes, even if adjusted for
LVM/h2.7 and urinary albumin excretion values (Table 5).
5. Discussion and Conclusion
To our knowledge this is the ﬁrst study to investigate the
impact of TGFβ1L e u→ Pro at codon 10 polymorphism
(rs1800470) on left ventricular geometry and function in
hypertensive patients. Our data indicate a higher prevalence
of TC and CC Leu10 →Pro polymorphism in hypertensives
with LVH than hypertensives without LVH, associated to
some unfavorable clinical characteristics of hypertension. In
fact, LVH hypertensive subjects with TC or CC genotype
were characterized by a higher prevalence of subjects with
microalbuminuria, higher value of LVM and lower left
ventricular ejection fraction. In our opinion, this association
doesn’t reﬂect unknown diﬀerences in population ancestry
between the two hypertensive groups. We consider the prob-
ability of false positive inference attributable to population
studied rather small because the two hypertensive groups
were recruited from an ethnically homogenous population.
In this context recent results from Xu et al. [22] revealed
a genetic association of TGFβ1 + 915 Arg → Pro at codon
25 polymorphism with LVH in a Chinese hypertensive
population, while the codon 10 genotypes did not show any
association to LVH. Even if in this study we have analyzed
only TGFβ1L e u→ Pro at codon 10 polymorphism, our
recent unpublished data indicated no association between
TGFβ1 + 915 Arg → Pro at codon 25 polymorphism
Table 3: Renal measurements, Circulating TGFβ1a n dP r o - c o ll a g e n
III in hypertensives with left ventricular hypertrophy subgrouped
according to Leu10 → Pro10 TGFβ1g e n o t y p e s .
TT n. 30 TC n. 128 CC n. 40
BUN (mg/dL) 39 ± 63 8 ± 73 9 ± 8
Creatinine (μmol/L) 61.9 ±17.7 79.6 ± 17.7 79.6 ± 17.7
Clearance (mL/min) 108 ± 30 103 ± 38 102 ± 32
UAE (mg/24h) 51 ± 40 113 ± 36∗ 92 ± 69∗
Microalbuminuric 5/30 80/128 21/40
pts (%) (16.7%) (62.5%)∗ (52.5%)∗
TGFβ1 (ng/mL) 45 ± 22 60 ± 15∗ 58 ± 11∗
PIIIP (U/L) 0.60 ± 0.1 0.71 ± 0.1∗ 0.65 ± 0.1∗
BUN: Blood urea nitrogen; TGFβ1: Transforming growth factor β1; PIIIP:
amino-terminal propeptide of type III procollagen; UAE: Urinary albumin
excretion; pts: patients.
∗P <. 05 versus TT.
Table 4: Left ventricular geometry and function in hypertensives
with left ventricular hypertrophy subgrouped according to Leu10 →
Pro10 TGFβ1g e n o t y p e s .
TT n. 30 TC n. 128 CC n. 40
LVIDd (mm) 49 ± 34 8 ± 44 8 ± 5
IVSTd (mm) 11 ± 1 11.9 ± 2 11,8 ± 2
PWTd (mm) 9.6 ± 1 10.5 ± 2 10.6 ± 1
RWT 0.39 ± 0.1 0.44 ± 0.1 0.44 ± 0.1
LVM (gr) 197 ± 33 228 ± 40∗ 216 ± 55∗
LVM/h2.7 (gr/h2.7)5 3 ± 85 9 ± 10∗ 56 ± 9∗
EF % 63 ± 35 7 ± 2∗ 56 ± 3∗
E/A 1.5 ± 0.4 1.4 ± 0.3 1.4 ± 0.4
DTE (ms) 202 ± 38 204 ± 42 205 ± 44
IVRT (ms) 80 ± 12 78 ± 15 81 ± 14
LVIDd: Left ventricular telediastolic internal diameter; IVSTd: Interven-
tricular septum thickness; PWTd: Posterior wall thickness; LVM: Left
ventricular mass; LVM/h2.7: Left ventricular mass indexed 2.7; RWT:
Relative wall thickness; EF: Ejection fraction; E/A: Peak early transmitral
ﬂow/peak late transmitral ﬂow; DTE: E deceleration time; IVRT: Isovolumic
relaxation time.
∗P<. 05 versus TT.
and hypertension in a Caucasian hypertensive population.
These contrasting data may be explained by ethnicity of
two hypertensive populations considered (Caucasian and
Chinese).
Although changes in the heart caused by hypertension
are well known, the eﬀective mechanisms are not entirely
clariﬁed. Despite the role of hemodynamic eﬀects and
growth factors have been largely reported, other metabolic
and inﬂammatory factors have to be also considered [23].
Literature data and the results of our previous stud-
ies indicate an overproduction of circulating TGFβ1i n
hypertensives. Moreover, hypertensives with target organ
damage (TOD) have higher circulating levels of TGFβ1
than hypertensives without TOD. This ﬁnding seems to
attribute an important role to TGFβ1 overproduction in the
pathophysiology of essential hypertension and its sequelae6 International Journal of Hypertension
Table 5: Logistic regressionanalysis.Deviance (likelihood ratio)chi-
square = 14,281753 df = 3 P = .0025.
Independent variable O.R∗ P=
PIIIP 8.1 (C.I: 1.50–15.20) .0466
UAE 4.3 (C.I: 0.93–8.43) .0814
LVM/h2.7 2.58 (C.I: 0.57–4.34) .203
logit y = −0,142938 + 2,090717 PIIIP+1,461049 UAE+0,949264 LVM/h2.7.
logit y = 1f o rT C+C Cg e n o t y p e s .
logit y = 0f o rT Tg e n o t y p e .
O.R.= odd ratio; C.I = Conﬁdence interval.
∗Odd ratio is referred to quintile variation of each variable.
[24, 25]. The TGFβ1 overproduction in hypertension may
be explained by the eﬀects of various factors, such as
elevated angiotensin II, increased ﬂuid shear stress and a
diﬀerential expression of TGFβ1 linked to DNA polymor-
phismsinthepromoter[11].Plasmaconcentrationsofactive
and also of acid-activable TGFβ1 is predominantly under
genetic control (heritability estimate 0.54). Up regulation
of TGFβ1 system in monocytes of hypertensive patients
and association of TGFβ1 gene polymorphism with risk of
hypertension suggests that quantitative diﬀerence in TGFβ1
production may determine the intensity of the process
of vascular remodelling and therefore inﬂuence overall
susceptibility to the development of hypertension [26]. On
the other hand experimental data indicate that abnormalities
in responsiveness to TGFβ1 overproduction, as evidenced
by collagen formation, may represent a pathophysiological
molecular mechanism in hypertension [27, 28]. The results
from ECTIM study [12] suggest that TGFβ1 Arg25-Pro
polymorphism might be associated with hypertension but
does not address the issue of quantitative phenotypes related
to TGFβ1 production in relation to hypertension. On the
contrary no study has been addressed the evaluation of the
role of Leu-to-Pro polymorphism at codon 10 to explain
whether the substitution has functional and biological
importance, or it could aﬀect protein transport. In view
of this we have now shown that the serum concentration
of TGFβ1 was signiﬁcantly diﬀerent in LVH hypertensives
subgrouped according to T29 → C polymorphism. It is
possiblethattheT29 → CpolymorphismoftheTGFβ1gene
is linked to some other genes that are actually responsible for
the development of hypertension.
Moreover, the signiﬁcant change in circulating TGFβ1
values among LVH hypertensive groups indicated that TC or
CC genotypes could be able to induce quantitative change in
the production of the cytokine and it might aﬀect also the
function of signal peptide, perhaps inﬂuencing intracellular
traﬃcking or export eﬃciency of preprotein [15].
In addition, our data suggest some clinical consider-
ations. First, LVH hypertensive subjects with TC or CC
genotypeswerecharacterizedbyahighervalueofmicroalbu-
minuria, LVM and by a systolic left ventricular dysfunction.
This might indicate that hypertension in these subjects
has to be considered more severe. Another aspect of our
study that seems to be interesting is related to the higher
collagen production in LVH hypertensive subjects with TC
or CC genotype than in those homozygous for allele T.
This ﬁnding is further supported by analysis of logistic
regression indicating that PIIIP may be considered the most
important marker associated to T and C alleles. In fact,
analysis of odd ratio indicates that the risk of association
with T or C allele increases eight fold for each PIIIP quintile
variation. In our opinion this ﬁnding might further support
our previous results [5, 23] indicating that overproduction
in circulating TGFβ1 may contribute to the progression of
renal and cardiovascular damage in obese and/or hyperten-
sive subjects. In particular, the present study emphasizes
the unfavourable eﬀects of TGFβ1o v e r p r o d u c t i o no nl e f t
ventricular geometry and function that might be mediated
by an higher collagen production [5, 24, 29]. In view of
this the association of TC or CC with a higher clinical
severity of hypertension seems to indicate that TGFβ1i sa
susceptibility locus for hypertension. A potential limit of this
study was to have computed no a priori evaluation of the β
error and consequently the power of our statistical analysis.
However this involves considerations only about the sample
size. Accordingly the negative results of our study has needed
further evaluations.
In conclusion our data are attractive to indicate that LVH
hypertensive subjects with TC or CC genotypes (Leu10 →
Pro polymorphism, rs 1800470) might be considered a
particular subset of LVH hypertensives with a more sever-
ity of hypertension. However, the present results require
veriﬁcations in other populations, since it is well known
that hypertension is under the control of many genes that
contribute modest individual eﬀects, and TGFβ1m a ya c ti n
concert with other hypertension susceptibility loci.
Acknowledgments
This study was in part supported by a project grant
from Ministero dell’Universit` aed e l l aR i c e r c a( p r o t .N
2004069479).
References
[1] A. V. Chobanian, G. L. Bakris, H. R. Black, et al., “The
seventh report of the joint national committee on prevention,
detection, evaluation, and treatment of high blood pressure:
the JNC 7 report,” Journal of the American Medical Association,
vol. 289, no. 19, pp. 2560–2572, 2003.
[2] K. T. Weber, “Fibrosis and hypertensive heart disease,” Current
Opinion in Cardiology, vol. 15, no. 4, pp. 264–272, 2000.
[3] C.Laviades,N.Varo,andJ.D´ ıez,“Transforminggrowthfactor
β in hypertensives with cardiorenal damage,” Hypertension,
vol. 36, no. 4, pp. 517–522, 2000.
[4] G. Parrinello, A. Licata, D. Colomba, et al., “Left ventricular
ﬁlling abnormalities and obesity-associated hypertension:
relationship with overproduction of circulating transforming
growth factor β1,” Journal of Human Hypertension, vol. 19, no.
7, pp. 543–550, 2005.
[5] R. Scaglione, C. Argano, G. Parrinello, et al., “Relationship
between transforming growth factor β1 and progression of
hypertensive renal disease,” Journal of Human Hypertension,
vol. 16, no. 9, pp. 641–645, 2002.International Journal of Hypertension 7
[6] F. Kuwahara, H. Kai, K. Tokuda, et al., “Transforming growth
factor-β function blocking prevents myocardial ﬁbrosis and
diastolicdysfunctioninpressure-overloadedrats,”Circulation,
vol. 106, no. 1, pp. 130–135, 2002.
[7] E. M. Zeisberg, O. Tarnavski, M. Zeisberg, et al., “Endothelial-
to-mesenchymal transition contributes to cardiac ﬁbrosis,”
Nature Medicine, vol. 13, no. 8, pp. 952–961, 2007.
[8] R. Scaglione, C. Argano, S. Corrao, T. Di Chiara, A. Licata,
and G. Licata, “Transforming growth factor β1 and additional
renoprotective eﬀect of combination ACE inhibitor and
angiotensin II receptor blocker in hypertensive subjects with
minor renal abnormalities: a 24-week randomized controlled
trial,” Journal of Hypertension, vol. 23, no. 3, pp. 657–664,
2005.
[9] R. Scaglione, C. Argano, T. Di Chiara, et al., “Eﬀect of dual
blockade of renin-angiotensin system on TGFβ1a n dl e f t
ventricular structure and function in hypertensive patients,”
Journal of Human Hypertension, vol. 21, no. 4, pp. 307–315,
2007.
[10] L. J. Ellmers, N. J. A. Scott, S. Medicherla, et al., “Trans-
forming growth factor-β blockade down-regulates the renin-
angiotensin system and modiﬁes cardiac remodeling after
myocardial infarction,” Endocrinology, vol. 149, no. 11, pp.
5828–5834, 2008.
[11] P. J. Lijnen, V. V. Petrov, and R. H. Fagard, “Association
between transforming growth factor-β and hypertension,”
American Journal of Hypertension, vol. 16, no. 7, pp. 604–611,
2003.
[12] F. Cambien, S. Ricard, A. Troesch, et al., “Polymorphisms of
the transforming growth factor-β1 gene in relation to myocar-
dial infarction and blood pressure: the etude cas-temoin de
l’infarctus du myocarde (ECTIM) study,” Hypertension, vol.
28, no. 5, pp. 881–887, 1996.
[13] M. R. Awad, A. El-Gamel, P. Hasleton, et al., “Genotypic
variation in the transforming growth factor-β1 gene: associ-
ation with transforming growth factor-β1 production, ﬁbrotic
lung disease, and graft ﬁbrosis after lung transplantation,”
Transplantation, vol. 66, no. 8, pp. 1014–1020, 1998.
[14] M. Yokota, S. Ichihara, T.-L. Lin, N. Nakashima, and Y.
Yamada, “Association of a T29→C polymorphism of the
transforming growth factor- β1 gene with genetic susceptibil-
ity to myocardial infarction in Japanese,” Circulation, vol. 101,
no. 24, pp. 2783–2787, 2000.
[15] B. Li, A. Khanna, V. Sharma, T. Singh, M. Suthanthiran, and
P. August, “TGF-β1 DNA polymorphisms, protein levels, and
blood pressure,” Hypertension, vol. 33, no. 1, pp. 271–275,
1999.
[16] W. Koch, P. Hoppmann, J. C. Mueller, A. Schomig, and A.
Kastrati, “Association of transforming growth factor-β1g e n e
polymorphisms with myocardial infarction in patients with
angiographicallyprovencoronaryheartdisease,”Arteriosclero-
sis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. 1114–
1119, 2006.
[17] A. Khanna, B. Li, K. H. Stenzel, and M. Suthanthiran,
“Regulation of new DNA synthesis in mammalian cells
by cyclosporine: demonstration of a transforming growth
factor β-dependent mechanism of inhibition of cell growth,”
Transplantation, vol. 57, no. 4, pp. 577–582, 1994.
[18] J. Risteli, S. Niemi, P. Trivedi, O. Maentausta, A. P. Mowat,
and L. Risteli, “Rapid equilibrium radioimmunoassay for the
amino-terminal propeptide of human type III procollagen,”
Clinical Chemistry, vol. 34, no. 4, pp. 715–718, 1988.
[19] G. de Simone, S. R. Daniels, R. B. Devereux, et al., “Left
ventricular mass and body size in normotensive children
and adults: assessment of allometric relations and impact of
overweight,” Journal of the American College of Cardiology, vol.
20, no. 5, pp. 1251–1260, 1992.
[20] G.Licata,R.Scaglione,S.Corrao,etal.,“Heredityandobesity-
associated hypertension: impact of hormonal characteristics
and left ventricular mass,” Journal of Hypertension, vol. 13, no.
6, pp. 611–618, 1995.
[21] D. W. Hosmer and S. Lemeshow, Applied Logistic Regression,
John Wiley & Sons, New York, NY, USA, 2000.
[ 2 2 ]H .Y .X u ,X .W .H u ,L .F .W a n g ,N .F .W a n g ,a n dJ .X u ,
“Association between transforming growth factor β1a n dl e f t
ventricular hypertrophy in essential hypertensive subjects,”
Molecular and Cellular Biochemistry, vol. 335, no. 1-2, pp. 13–
17, 2010.
[23] A. V. Villar, M. Llano, M. Cobo, et al., “Gender diﬀerences
of echocardiographic and gene expression patterns in human
pressure overload left ventricular hypertrophy,” Journal of
Molecular and Cellular Cardiology, vol. 46, no. 4, pp. 526–535,
2009.
[24] R. Scaglione, C. Argano, T. Di Chiara, et al., “Central obesity
and hypertensive renal disease: association between higher
levels of BMI, circulating transforming growth factor β1a n d
urinaryalbuminexcretion,”BloodPressure,vol.12,no .5-6,pp .
269–276, 2003.
[25] U. Derhaschnig, M. Shehata, H. Herkner, et al., “Increased
levels of transforming growth factor-β1 in essential hyperten-
sion,”AmericanJournalofHypertension,vol.15,no.3,pp.207–
211, 2002.
[26] E. Porreca, C. Di Febbo, G. Mincione, et al., “Increased
transforminggrowthfactor-β production and gene expression
by peripheral blood monocytes of hypertensive patients,”
Hypertension, vol. 30, no. 1, pp. 134–139, 1997.
[27] N. Fukuda, W.-Y. Hu, A. Kubo, et al., “Abnormal regula-
tion of transforming growth factor-β receptors on vascular
smooth muscle cells from spontaneously hypertensive rats by
angiotensinII,”Hypertension,vol.31,no.2,pp.672–677,1998.
[28] P. Bray, A. Agrotis, and A. Bobik, “Transforming growth
factor-β and receptor tyrosine kinase-activating growth fac-
tors negatively regulate collagen genes in smooth muscle of
hypertensive rats,” Hypertension, vol. 31, no. 4, pp. 986–994,
1998.
[29] O. Soylemezoglu, G. Wild, A. J. Dalley, et al., “Urinary and
serum type III collagen: markers of renal ﬁbrosis,” Nephrology
Dialysis Transplantation, vol. 12, no. 9, pp. 1883–1889, 1997.